Posted Feb 25, 2020
•
8 min read
Mammoth Expands Bio-Platform Network Effects to Gene-Editing
Announcing Mammoth Biosciences' $45M Series B Mammoth is now the bio-platform for next-generation CRISPR products across therapeutics and diagnostics. NFX portfolio company Mammoth Biosciences today announced a $45M Series B, led by Decheng Capital, with participation from Alphabet's Verily Life Sciences and Brook Byers of Kleiner Perkins, among others. Additionally, Mammoth Dr. Min Cui, Ph.D., of Decheng, Jeff ... Continue reading "Mammoth Expands Bio-Platform Network Effects to Gene-Editing"
More Ways to Read:
🧃
Summarize
--
The key takeaways that can be read in under a minute
Sign up to unlock
Worth the squeeze
Get access to the condensed version of this piece, and every other article on The Juice, and so much more.
Start a free account on The Juice and we'll send you weekly emails sharing which podcasts, blogs, guides,
etc. are trending with other marketing or sales pros. We call it the Top 5!
Other content from
NFX
Featured by Brave
